Brand names appearing in italics throughout this report are trademarks of <strong>Aventis</strong> and/or its affiliates, with the exception of: - trademarks used or that may be used under license by <strong>Aventis</strong> and / or its affiliates, such as Actonel, a trademark of the Group Procter & Gamble Pharmaceuticals, Alvesco, a trademark of the Group ALTANA Pharma AG, Campto, a trademark of the Group Kabushiki Kaisha Yakult Honsha, Copaxone, a trademark of the Group Teva Pharmaceutical Industries, DiaPep277, a trademark of Peptor Ltd, Exubera, a trademark of the Group Pfizer Products Inc., Genasense, a trademark of Genta Inc. in the U.S., Tavanic, a trademark of the Group Daiichi Pharmaceutical Co. Ltd. and Mutagrip, a trademark of Institut Pasteur. - Claritin, a trademark of Schering Corporation Information Regarding Forward-Looking Statements Statements in this annual report other than historical information are forward-looking statements subject to risks and uncertainties. The forward-looking statements in this document speak only of management’s views as at March 1, 2004. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, impediments to the realization of integration cost savings as a result of labor or political issues or the difficulties of integrating large and complex businesses while continuing day-to-day operations, continued evolutions in the business and business environment, actions that may be taken by competitors or by regulatory authorities, unexpected negative results from research and development of current product candidates, the effectiveness of patent protection, the result of litigation and other risks and uncertainties that are difficult to predict. There can be no assurance that we will achieve the results set forth above. Additional information regarding risks and uncertainties is set forth in the current <strong>Annual</strong> <strong>Report</strong> on Form 20-F of <strong>Aventis</strong> on file with the U.S. Securities and Exchange Commission. This report has been provided for information purposes only. <strong>Aventis</strong> prepares a legally binding annual report in the French language known as the “Document de Référence” prior to its <strong>Annual</strong> General Meeting of Shareholders as well as an annual report in the English language on Form 20-F pursuant to the U.S. Securities Exchange Act of 1934. All reports can be ordered by phone: 00 800 40 53 43 40 (toll-free) or +49 6192 9 77 08 28 or by e-mail: <strong>Aventis</strong>@mt-w.de They can also be downloaded from our Web site at www.aventis.com <strong>Aventis</strong>, a stock corporation with a Supervisory Board and Management Board, and a share capital of e 3 064 758 522.74 – 542 064 308 RCS Strasbourg
<strong>Aventis</strong> 67917 Strasbourg Cedex 9 · France · www.aventis.com
Change language